Study: T2D Therapy With Weekly DPP-4 Inhibitor Feasible

From the news wire:

An investigational weekly DPP-4 inhibitor proved noninferior to daily alogliptin (Nesina) among Japanese patients in a phase III study, researchers reported.
Weekly trelagliptin reduced HbA1c to similar levels as the daily drug, and the difference was below the noninferiority margin of 0.4%, Nobuya Inagaki, MD, PhD, of Kyoto University, and colleagues reported online in the Lancet Diabetes and Endocrinology.

Source: http://www.medpagetoday.com/Endocrinology/Diabetes/49646